finance.yahoo.com
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment discussions and expectations about long-term effectiveness.
Adults with moderately to severely active Crohn's disease (including those with prior biologic failure), clinicians treating IBD, researchers following IL-23 therapies, and patients on or considering biologic treatments.
What To Know
What To Know Lilly reported results from the VIVID-2 open-label extension showing that most patients with moderately to severely active Crohn's disease who stayed on Omvoh (mirikizumab-mrkz) for two continuous years maintained clinical remission and endoscopic response measured during the trial.
The release highlights observed-case analyses (for example, 92.9% maintained CDAI-defined clinical remission from year one to year two, and 87.6% maintained endoscopic response) and notes results were also evaluated with a modified non-responder imputation method.
Safety during the second year was described as generally consistent with the known profile of Omvoh, with 6.8% of patients with endoscopic response reporting a serious adverse event and 0.8% discontinuing due to an adverse event.
This is a company press release summarizing trial extension data that Lilly says will be presented at the Crohn's and Colitis Congress. It reports trial design details (VIVID-1 dosing/route and continuation into VIVID-2) and regulatory milestones (FDA approval for Crohn's disease in January 2025 and EMA positive opinion).
The release also mentions ongoing and planned studies, including pediatric and Phase 4 real-world studies.
If you are reading this because you or someone you care for is using or considering Omvoh, this release suggests durable clinical and endoscopic responses in the trial population over two years, but it does not provide individual treatment advice, full study data, or independent peer-reviewed analysis.
This is a company press release summarizing open-label extension data; full study results and independent peer-reviewed publications or conference presentations should be consulted for complete methods, statistical analyses, and safety details.
Reported percentages are from observed-case analyses and other imputation methods were used; press releases may emphasize positive outcomes.
